SavedAdd your journal

Journals / Marmara Medical Journal / 2026 / Volume: 25 Issue: 2

-

Lokal İleri Evre Özefagus Kanserinde Kemoradyoterapi Deneyimimiz

İlknur Alsan Çetin
P. Öncü Yumuk
Beste Atasoy
Faysal Dane
Hale Çağlar
Roman İbrahimov
Hasan Batırel
Ufuk Abacıoğlu
Pages
—
Publication Date
2015-03-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗

Abstract

-

Özet

Amaç: Bu çalışmada lokal ileri evre özefagus kanseri tanısıyla neoadjuvan/ definitif kemoradyoterapi (KRT) uygulanan hastaların sonuçlarının bildirilmesi amaçlanmıştır. Hastalar ve Yöntem: Histolojik tanısı skuamöz hücreli 10, adenokarsinom 4, adenoskuamöz karsinom 1 olan, T3N0M0 5 veya T3N1M0/T4N0M0 10, toplam 15 hasta geriye dönük olarak incelendi. Ortanca radyoterapi dozu 50 Gy (1,8-2 Gy/gün, 5 fraksiyon/hafta) olup eş zamanlı kemoterapi radyoterapinin ilk ve son hafta sisplatin ve 5-florourasil olarak uygulandı. Bulgular: Eş zamanlı kemoterapinin kesintisiz uygulanabilirlik oranı %80 idi. Medyan takip 15 ay (aralık, 3-70 ay) idi. Neoadjuvan olarak tedavi edilen beş hastadan birinde lokal progresyon, üçünde uzak metastaz izlendi. Baştan definitif KRT planlanan hastalardan üçüne (%30) evrede küçülme izlenerek cerrahi önerildi. İki yıllık lokal kontrol (LK) %22, uzak metastazsız sağkalım (UMSK) %45 ve genel sağkalım (GSK) %31 olarak saptandı. Derece III disfaji oranı %6 idi. Sonuç: Lokal ileri evre özefagus kanserinde tedavi tartışmalıdır. Cerrahi şansını elde eden hastalarda daha uzun sağkalım ve lokal kontrol bildirilirken üçlü modalite tedavilerin yapılabilirliği merkezin deneyimi ile sınırlıdır. Bu nedenle tüm hastalar bireysel olarak ve multidisipliner yaklaşım ile değerlendirilmelidir. (Marmara Üniversitesi Tıp Fakültesi Dergisi 2012;25:74-7) Anahtar Kelimeler: Cerrahi, Lokal ileri evre, Kemoradyoterapi, Özefagus kanseri

🔖

Cite This Article

Çetin, İ. A., Yumuk, P. Ö., Atasoy, B., Dane, F., Çağlar, H., İbrahimov, R., Batırel, H., Abacıoğlu, U. (2015). -. Marmara Medical Journal, Volume: 25 Issue: 2. https://ajindex.com/articles/1286957

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (71)

  1. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin; 60: 277–300. doi: 10.3322/caac.20073
  2. Sagar PM, Gauperaa T, Suc-Ling H, et al. An audit of the treatment of the
  3. cancer of the oesophagus. Gut 1994; 35: 941-5.
  4. Daly JM, Karnell LH, Menck HR. National Cancer Data Base report on
  5. esophageal carcinoma. Cancer 1996; 78: 1820-8. doi: 10.1002/
  6. (SICI)1097-0142(19961015)78:8<1820
  7. Kelsen DP, Ginsberg R, Pajak TF, et al. Chemotherapy followed by surgery
  8. compared with surgery alone for localized esophageal cancer. N Eng J
  9. Med 1998; 339:1979-84.
  10. Herskovic A, Martz K, Al-Sarraf MV, et al. Combined chemotherapy and
  11. radiotherapy compared with radiotherapy alone in patients with cancer
  12. of the esophagus. N Eng J Med 1992; 326: 1593-8.
  13. Boset JF, Gignoux M, Triboulet JP, et al. Chemoradiatherapy followed by
  14. surgery compared with surgery alone in squamous cell cancer of the
  15. esophagus. N Eng J Med 1997; 337: 161-7.
  16. Gebski V, Burmeister B, Smithers BM, et al. Survival benefits from
  17. neoadjuvant chemoradiotherapy or chemotherapy in esophageal
  18. carcinoma: a meta-analysis. Lancet Oncol 2007;8:226–34. doi:10.1016/
  19. S1470-2045(07)70039-6
  20. Greer SE, Goodney PP, Sutton JE, et al. Neoadjuvant chemoradiotherapy
  21. for esophageal carcinoma: A meta-analysis. Surgery 2005; 137:172-7.
  22. doi:10.1016/j.surg.2004.06.033
  23. Fiorica F, Di Bona D, Schepis F, et al. Preoperative chemoradiotherapy for
  24. oesophageal cancer: A systematic review and meta-analysis. Gut 2004;:925-30. doi:10.1136/gut.2003.025080
  25. Urschel JD, Vasan H. A meta-analysis of randomized controlled trials that
  26. compared neoadjuvant chemoradiation and surgery to surgery alone for
  27. resectable esophageal cancer. Am J Surg 2003;185:538-43.
  28. doi:10.1016/S0002-9610(03)00066-7
  29. Graham AJ, Shrive FM, Ghali WA, et al. Defining the optimal
  30. treatment of locally advanced esophageal cancer: A systematic review
  31. and decision analysis. Ann Thorac Surg 2007; 83:1257-64.
  32. doi:10.1016/ j.athoracsur.2006.11.061
  33. Coia LR, Engstrom PF, Paul AR, et al. Long-term results of infusional 5-FU,
  34. mitomycin-C, and radiation as primary management of esophageal
  35. carcinoma. Int J Radiat Oncol Biol Phys 1991;20:29-36.
  36. doi:10.1016/0360-3016(91)90134-P
  37. Wong RK, Malthaner RA, Zuraw L, et al. Cancer Care Ontario Practice
  38. Guidelines Initiative Gastrointestinal Cancer Disease Site Group.
  39. Combined modality radiotherapy and chemotherapy in nonsurgical
  40. management of localized carcinoma of the esophagus: a practice
  41. guideline. Int J Radiat Oncol Biol Phys 2003; 55:930-42.
  42. doi:10.1016/S0360-3016(02)04278-5
  43. Cooper JS, Guo MD, Herskovic A, et al. Chemoradiotherapy of locally
  44. advanced esophageal cancer: long-term follow-up of a prospective
  45. randomized trial (RTOG 85-01). Radiation Therapy Oncology Group
  46. JAMA. 1999; 281:1623-7.
  47. al-Sarraf M, Martz K, Herskovic A, et al. Progress report of combined
  48. chemoradiotherapy versus radiotherapy alone in patients with
  49. esophageal cancer: an intergroup study. J Clin Oncol 1997;15:277-84.
  50. Bedenne L, Michel P, Bouché O, et al. Chemoradiation followed by surgery
  51. compared with chemoradiation alone in squamous cancer of the
  52. esophagus: FFCD 9102. J Clin Oncol 2007; 25:1160-8. doi:
  53. JCO.2005.04.7118
  54. Walsh TN, Noonan N, Hollywood D, et al. A comparison of multimodal
  55. therapy and surgery for esophageal adenocarcinoma. N Engl J Med 1996;:462-7. doi: 10.1056/NEJM199608153350702
  56. Urba SG, Orringer MB, Turrisi A, et al. Randomized trial of preoperative
  57. chemoradiation versus surgery alone in patients with locoregional
  58. esophageal carcinoma. J Clin Oncol 2001;19:305-13.
  59. Burmeister BH, Smithers BM, Gebski V, et al. Surgery alone versus
  60. chemoradiotherapy followed by surgery for resectable cancer of the
  61. oesophagus: A randomised controlled phase III trial. Lancet Oncol;6:659-68. doi:10.1016/S1470-2045(05)70288-6
  62. Tepper J, Krasna MJ, Niedzwiecki D, et al. Phase III trial of trimodality
  63. therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared
  64. with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol;26:1086-92. Doi: 10.1200/JCO.2007.12.9593
  65. Minsky BD, Pajak TF, Ginsberg RJ, et al. INT 0123 (Radiation Therapy
  66. Oncology Group 94-05) phase III trial of combined-modality therapy for
  67. esophageal cancer: high-dose versus standard-dose radiation therapy. J
  68. Clin Oncol 2002;20:1167-74.
  69. Common Toxicity Criteria v.3.0. http://www.eortc.be/services/
  70. doc/ctc/default.htm. Erişim tarihi 16.09.2011
  71. guideline. Int J Radiat Oncol Biol Phys 2003; 55:930-42.